GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2025, recommended Final Dividend of Rs. 42 per equity share.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors met on May 13, 2025 and approved audited financial results for the quarter and year ended March 31, 2025. Standalone revenue for FY25 rose to Rs. 3,72,349 lakhs from Rs. 3,40,725 lakhs a year ago (about 9% growth), while standalone profit after tax jumped to Rs. 91,906 lakhs from Rs. 58,469 lakhs, helped by lower exceptional charges compared to last year's VRS cost. EPS (after exceptional items) stood at Rs. 54.24 (standalone) and Rs. 54.76 (consolidated). The Board recommended a final dividend of Rs. 42 per equity share (face value Rs. 10), up 31% from Rs. 32 in the previous year, subject to shareholder approval at the 100th AGM on June 27, 2025. The record date is May 30, 2025 and dividend payment will begin from June 30, 2025. The Board also re-appointed Dr. Sunita Maheshwari as Independent Director for a second term of three years and appointed Parikh & Associates as Secretarial Auditor for five years from FY25-26 to FY29-30.
A 31% hike in the final dividend signals strong cash generation and management's confidence, and is likely to be viewed positively by income-focused shareholders. The sharp jump in FY25 profit is partly aided by the absence of last year's one-off VRS charge, so underlying earnings growth is more modest; still, the results and dividend bump should provide near-term support to the stock.